Doripenem

Results: 18



#Item
1Doripenem DEKLARATION Doripenem (J01DH04) är ett parenteralt betalaktamantibiotikum tillhörande karbapenemgruppen med brett antibakteriellt spektrum och stabilitet mot flertalet betalaktamaser.

Doripenem DEKLARATION Doripenem (J01DH04) är ett parenteralt betalaktamantibiotikum tillhörande karbapenemgruppen med brett antibakteriellt spektrum och stabilitet mot flertalet betalaktamaser.

Add to Reading List

Source URL: www.sls.se

Language: Swedish - Date: 2014-11-03 03:38:30
    2Shionogi & Co., Ltd.  Shionogi Receives Approval of Additional Dosage and Administration of Carbapenem Antibiotic Products: ® “Finibax 0.25g IV Solution” and “Finibax® 0.25g IV Solution Kit”

    Shionogi & Co., Ltd. Shionogi Receives Approval of Additional Dosage and Administration of Carbapenem Antibiotic Products: ® “Finibax 0.25g IV Solution” and “Finibax® 0.25g IV Solution Kit”

    Add to Reading List

    Source URL: shionogi616.tew-staging.com

    Language: English - Date: 2014-11-03 11:26:18
    3January 25, 2010 Shionogi & Co., Ltd. Shionogi Supports Relief Efforts for Haiti Earthquake Victims Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President: Isao Teshirogi; hereafter “Shionogi”) today announced th

    January 25, 2010 Shionogi & Co., Ltd. Shionogi Supports Relief Efforts for Haiti Earthquake Victims Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President: Isao Teshirogi; hereafter “Shionogi”) today announced th

    Add to Reading List

    Source URL: shionogi616.tew-staging.com

    Language: English - Date: 2014-11-03 11:26:18
    4Shionogi Receives Approvals of Pediatric Use and Additional Indication for Purulent Meningitis of Carbapenem-Type Antibiotic, ® “Finibax 0.25g/0.5g for Intravenous Drip Infusion” and “Finibax® 0.25g Kit for Intra

    Shionogi Receives Approvals of Pediatric Use and Additional Indication for Purulent Meningitis of Carbapenem-Type Antibiotic, ® “Finibax 0.25g/0.5g for Intravenous Drip Infusion” and “Finibax® 0.25g Kit for Intra

    Add to Reading List

    Source URL: shionogi616.tew-staging.com

    Language: English - Date: 2014-11-03 11:26:21
    5Microsoft Word - OspemifeneNDA20120426

    Microsoft Word - OspemifeneNDA20120426

    Add to Reading List

    Source URL: shionogi616.tew-staging.com

    Language: English - Date: 2014-11-03 11:26:21
    6   Shionogi Launches New European Headquarters in London London, 5thJulyJapanese based pharmaceutical company Shionogi & Co., Ltd (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionog

      Shionogi Launches New European Headquarters in London London, 5thJulyJapanese based pharmaceutical company Shionogi & Co., Ltd (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionog

    Add to Reading List

    Source URL: shionogi616.tew-staging.com

    Language: English - Date: 2014-11-03 11:26:24
    7Shionogi Launches Carbapenem-Type Antibiotic, “Finibax® 0.5g for Intravenous Drip Infusion” Osaka, Japan, November 29, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereaft

    Shionogi Launches Carbapenem-Type Antibiotic, “Finibax® 0.5g for Intravenous Drip Infusion” Osaka, Japan, November 29, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereaft

    Add to Reading List

    Source URL: shionogi616.tew-staging.com

    Language: English - Date: 2014-11-03 11:26:18
    8Rationale for the EUCAST clinical breakpoints

    Rationale for the EUCAST clinical breakpoints

    Add to Reading List

    Source URL: www.eucast.org

    Language: English - Date: 2009-12-12 17:12:59
    9Rationale for new or revised EUCAST clinical breakpoints Derek Brown ECCMID 2011, Milan  Setting breakpoints in EUCAST

    Rationale for new or revised EUCAST clinical breakpoints Derek Brown ECCMID 2011, Milan Setting breakpoints in EUCAST

    Add to Reading List

    Source URL: www.eucast.org

    Language: English - Date: 2011-05-25 13:06:52
    10———————WARNINGS AND PRECAUTIONS——————— Serious hypersensitivity (anaphylactic) reactions have been reported with carbapenems and other beta-lactams (5.1) •	 It has been shown that co-adminis

    ———————WARNINGS AND PRECAUTIONS——————— Serious hypersensitivity (anaphylactic) reactions have been reported with carbapenems and other beta-lactams (5.1) • It has been shown that co-adminis

    Add to Reading List

    Source URL: www.accessdata.fda.gov

    Language: English - Date: 2009-04-23 07:20:15